Altimmune, Inc. (NASDAQ:ALT) Stock Position Lifted by SG Americas Securities LLC

SG Americas Securities LLC raised its holdings in shares of Altimmune, Inc. (NASDAQ:ALT) by 36.7% in the 4th quarter, Holdings Channel reports. The firm owned 47,060 shares of the company’s stock after purchasing an additional 12,624 shares during the quarter. SG Americas Securities LLC’s holdings in Altimmune were worth $339,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently modified their holdings of the company. Larson Financial Group LLC acquired a new position in shares of Altimmune in the 3rd quarter valued at about $31,000. 180 Wealth Advisors LLC acquired a new position in Altimmune in the fourth quarter valued at approximately $78,000. Stifel Financial Corp grew its holdings in shares of Altimmune by 77.4% during the third quarter. Stifel Financial Corp now owns 17,752 shares of the company’s stock valued at $109,000 after purchasing an additional 7,746 shares during the last quarter. Creative Planning raised its position in shares of Altimmune by 20.5% during the 3rd quarter. Creative Planning now owns 18,411 shares of the company’s stock worth $113,000 after purchasing an additional 3,132 shares during the period. Finally, Centiva Capital LP bought a new stake in shares of Altimmune in the 3rd quarter worth approximately $120,000. 78.05% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. Stifel Nicolaus assumed coverage on Altimmune in a research note on Wednesday, January 8th. They set a “buy” rating and a $18.00 price objective for the company. HC Wainwright restated a “buy” rating and set a $12.00 price target on shares of Altimmune in a research report on Wednesday, January 22nd. Finally, UBS Group started coverage on shares of Altimmune in a research report on Tuesday, November 12th. They issued a “buy” rating and a $26.00 price objective on the stock. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Altimmune has an average rating of “Buy” and an average price target of $20.83.

Altimmune Stock Up 3.1 %

ALT stock opened at $6.64 on Wednesday. The company has a 50-day simple moving average of $7.70 and a 200 day simple moving average of $7.17. The company has a market capitalization of $472.24 million, a P/E ratio of -4.28 and a beta of 0.19. Altimmune, Inc. has a fifty-two week low of $5.28 and a fifty-two week high of $14.84.

Altimmune (NASDAQ:ALT) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.03. The company had revenue of $0.01 million during the quarter. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. During the same period in the prior year, the company posted ($0.39) earnings per share. Equities analysts anticipate that Altimmune, Inc. will post -1.35 EPS for the current year.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.